Oral ketamine for children with chronic pain: A pilot phase 1 study

Journal of Pediatrics

Volumn 163, Issue 1, 2013, Pages

  Bredlau, Amy Lee ^a   McDermott, Michael P ^b   Adams, Heather R ^b   Dworkin, Robert H ^b   Venuto, Charles ^c   Fisher, Susan G ^b   Dolan, James G ^b   Korones, David N ^b,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE;

ADOLESCENT; ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BEDTIME DOSAGE; CHILD; CHILL; CHRONIC PAIN; CLINICAL ARTICLE; CONFUSION; CONSCIOUSNESS LEVEL; CONSTIPATION; CYSTIC FIBROSIS; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSURIA; FATIGUE; FEMALE; HEADACHE; HUMAN; INFECTION; LUNG MYCOSIS; MALE; MAXIMUM PLASMA CONCENTRATION; MEMORY DISORDER; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; SCHOOL CHILD; SCORING SYSTEM; SEDATION; SIDE EFFECT; SOMNOLENCE; SORE THROAT; SPINAL DYSRAPHISM; THORAX PAIN; VOMITING;

EID: 84879410066     PISSN: 00223476     EISSN: 10976833     Source Type: Journal    
DOI: 10.1016/j.jpeds.2012.12.077     Document Type: Article

References (27)

1. C.B. Berde, G.A. Walco, E.J. Krane, K.J. Anand, J.V. Aranda, and K.D. Craig Pediatric analgesic clinical trial designs, measures, and extrapolation: report of an FDA scientific workshop Pediatrics 129 2012 354 364
2. S. King, C.T. Chambers, A. Huguet, R.C. MacNevin, P.J. McGrath, and L. Parker The epidemiology of chronic pain in children and adolescents revisited: a systematic review Pain 152 2011 2729 2738
3. S.M. Green, and C.J. Cote Ketamine and neurotoxicity: clinical perspectives and implications for emergency medicine Ann Emerg Med 54 2009 181 190
4. A.K. Mehta, S. Halder, N. Khanna, O.P. Tandon, and K.K. Sharma Antagonism of stimulation-produced analgesia by naloxone and N-methyl-D-aspartate: role of opioid and N-methyl-D-aspartate receptors Hum Exp Toxicol 31 2012 51 56
5. D.J. Smith, R.L. Bouchal, C.A. deSanctis, P.J. Monroe, J.B. Amedro, and J.M. Perrotti Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro Neuropharmacology 26 1987 1253 1260
6. T.R. Romero, G.S. Galdino, G.C. Silva, L.C. Resende, A.C. Perez, and S.F. Cortes Ketamine activates the L-arginine/nitric oxide/cyclic guanosine monophosphate pathway to induce peripheral antinociception in rats Anesth Analg 113 2011 1254 1259
7. Y. Hayashi, K. Kawaji, L. Sun, X. Zhang, K. Koyano, and T. Yokoyama Microglial Ca(2+)-activated K(+) channels are possible molecular targets for the analgesic effects of S-ketamine on neuropathic pain J Neurosci 31 2011 17370 17382
8. T. Okon Ketamine: an introduction for the pain and palliative medicine physician Pain Physician 10 2007 493 500
9. G.R. Lauretti, J.M. Gomes, M.P. Reis, and N.L. Pereira Low doses of epidural ketamine or neostigmine, but not midazolam, improve morphine analgesia in epidural terminal cancer pain therapy J Clin Anesth 11 1999 663 668
10. G.R. Lauretti, I.C. Lima, M.P. Reis, W.A. Prado, and N.L. Pereira Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management Anesthesiology 90 1999 1528 1533
11. S. Mercadante, E. Arcuri, W. Tirelli, and A. Casuccio Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study J Pain Sympt Manage 20 2000 246 252
12. C.Y. Yang, C.S. Wong, J.Y. Chang, and S.T. Ho Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain Can J Anaesth 43 1996 379 383
13. R.J. Schwartzman, G.M. Alexander, J.R. Grothusen, T. Paylor, E. Reichenberger, and M. Perreault Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study Pain 147 2009 107 115
14. M.J. Sigtermans, J.J. van Hilten, M.C. Bauer, M.S. Arbous, J. Marinus, and E.Y. Sarton Ketamine produces effective and long-term pain relief in patients with complex regional pain syndrome type 1 Pain 145 2009 304 311
15. C.L. von Baeyer, L.J. Spagrud, J.C. McCormick, E. Choo, K. Neville, and M.A. Connelly Three new datasets supporting use of the Numerical Rating Scale (NRS-11) for children's self-reports of pain intensity Pain 143 2009 223 227
16. V.D. Gupta Stability of ketamine hydrochloride injection after reconsitution in water for injection and storage in 1-mL tuberculin polypropylene syringes for pediatric use Int J Pharmaceut Compound 2002 316 317
17. I.S. Grant, W.S. Nimmo, and J.A. Clements Pharmacokinetics and analgesic effects of i.m. and oral ketamine Br J Anaesth 53 1981 805 810
18. J. O'Quigley, M. Pepe, and L. Fisher Continual reassessment method: a practical design for phase 1 clinical trials in cancer Biometrics 46 1990 33 48
19. S.N. Goodman, M.L. Zahurak, and S. Piantadosi Some practical improvements in the continual reassessment method for phase I studies Stat Med 14 1995 1149 1161
20. D. Bouhassira, N. Attal, H. Alchaar, F. Boureau, B. Brochet, and J. Bruxelle Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4) Pain 114 2005 29 36
21. R.H. Dworkin, D.C. Turk, J.T. Farrar, J.A. Haythornthwaite, M.P. Jensen, and N.P. Katz Core outcome measures for chronic pain clinical trials: IMMPACT recommendations Pain 113 2005 9 19
22. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. In: Health NIo, editor.2009.
23. G.S. Falchook, M. Duvic, D.S. Hong, J. Wheler, A. Naing, and J. Lim Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies Cancer Chemother Pharmacol 69 2012 1117 1126
24. Y. Hijazi, and R. Boulieu Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes Drug Metab Dispos 30 2002 853 858
25. T.B. Barclay, J.M. Peters, M.B. Sewer, L. Ferrari, F.J. Gonzalez, and E.T. Morgan Modulation of cytochrome P-450 gene expression in endotoxemic mice is tissue specific and peroxisome proliferator-activated receptor-alpha dependent J Pharmacol Exp Therap 290 1999 1250 1257
26. L.P. Rivory, K.A. Slaviero, and S.J. Clarke Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response Br J Cancer 87 2002 277 280
27. Y.L. Chen, V. Le Vraux, A. Leneveu, F. Dreyfus, A. Stheneur, and I. Florentin Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics Clin Pharmacol Therap 55 1994 649 660